Novira Therapeutics Inc., a Doylestown, MA-based clinical-stage company developing novel therapeutic candidates for curative treatments of chronic Hepatitis B virus (HBV) infection, has been acquired by Johnson & Johnson (NYSE: JNJ).
The financial terms of the transaction, whose closing is subject to customary closing conditions, have not been disclosed.
will enhance the ability of Novira’s research and development teams to continue to advance novel therapeutic candidates for chronic HBV infection.
Led by Christian S. Schade, Chief Executive Officer, Novira Therapeutics is advancing NVR 3-778, a small molecule, direct acting antiviral drug candidate that inhibits the HBV core or capsid protein, being investigated for oral administration in patients with Chronic Hepatitis B (CHB).
Investors in the company included Versant Ventures, 5AM Ventures and Canaan Partners.